MIRA Pharmaceuticals announced that its novel oral ketamine analogue, ketamir-2, showed improved pain relief in preclinical studies compared to gabapentin and pregabalin. This development highlights ketamir-2 as a potential alternative for patients suffering from neuropathic pain, providing effective relief without the risks associated with opioid use.
The study demonstrated that ketamir-2 outperformed pregabalin by 112% and gabapentin by 70% at higher doses. Unlike its counterparts, ketamir-2 has fewer cognitive side effects and no risk of dependence, making it safer for long-term use.
Given the growing global concern regarding neuropathic pain, MIRA aims to submit an investigational new drug application by the end of the year, with Phase 1 clinical trials planned for early 2025. The company is also exploring the potential of Ketamir-2 for the treatment of PTSD and other neuropsychiatric disorders, seeking government grants to accelerate its development.
R. P.
